| Literature DB >> 25205189 |
Sujeet Kumar1, Vidya Gopalakrishnan2, Mahesh Hegde2, Vivek Rana1, Sharad S Dhepe1, Sureshbabu A Ramareddy1, Alberto Leoni3, Alessandra Locatelli3, Rita Morigi3, Mirella Rambaldi3, Mrinal Srivastava2, Sathees C Raghavan2, Subhas S Karki4.
Abstract
A series of 2,5,6-substituted imidazo[2,1-b][1,3,4]thiadiazole derivatives have been prepared and were tested for antiproliferative activity on cancer cells at the National Cancer Institute. Results showed that molecules with a benzyl group at position 2, exhibited an increase in activity for the introduction of a formyl group at the 5 position. The compound 2-benzyl-5-formyl-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazole 22 has been chosen for understanding the mechanism of action by various molecular and cellular biology studies. Results obtained from cell cycle evaluation analysis, analysis of mitochondrial membrane potential and Annexin V-FITC by flow cytometric analysis, ROS production and expression of apoptotic and DNA-repair proteins suggested that compound 22 induced cytotoxicity by activating extrinsic pathway of apoptosis, however, without affecting cell cycle progression.Entities:
Keywords: Acute toxicity; Antiproliferative agents; Apoptosis; Cell-based screening assay; Hollow fiber assay; Imidazo[2,1-b][1,3,4]thiadiazoles
Mesh:
Substances:
Year: 2014 PMID: 25205189 DOI: 10.1016/j.bmcl.2014.08.032
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823